Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$392.81 - $485.53 $116,271 - $143,716
-296 Reduced 28.52%
742 $347,000
Q1 2024

May 07, 2024

SELL
$407.69 - $446.08 $28,130 - $30,779
-69 Reduced 6.23%
1,038 $433,000
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $14,406 - $17,248
-42 Reduced 3.66%
1,107 $450,000
Q3 2023

Nov 02, 2023

SELL
$338.18 - $362.46 $5,072 - $5,436
-15 Reduced 1.29%
1,149 $399,000
Q2 2023

Aug 08, 2023

SELL
$314.42 - $351.91 $364,412 - $407,863
-1,159 Reduced 49.89%
1,164 $409,000
Q1 2023

May 01, 2023

BUY
$283.23 - $323.1 $125,187 - $142,810
442 Added 23.5%
2,323 $731,000
Q4 2022

Feb 08, 2023

SELL
$285.76 - $321.48 $207,461 - $233,394
-726 Reduced 27.85%
1,881 $0
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $164,024 - $183,012
-599 Reduced 18.68%
2,607 $755 Million
Q2 2022

Aug 05, 2022

SELL
$234.96 - $292.55 $406,950 - $506,696
-1,732 Reduced 35.07%
3,206 $903,000
Q1 2022

May 04, 2022

SELL
$221.42 - $260.97 $2.95 Million - $3.47 Million
-13,304 Reduced 72.93%
4,938 $1.29 Million
Q4 2021

Feb 02, 2022

SELL
$177.01 - $223.45 $98,240 - $124,014
-555 Reduced 2.95%
18,242 $4.01 Million
Q3 2021

Nov 10, 2021

SELL
$181.39 - $202.99 $6.2 Million - $6.93 Million
-34,154 Reduced 64.5%
18,797 $3.41 Million
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $6.85 Million - $8.08 Million
36,560 Added 223.05%
52,951 $10.7 Million
Q1 2021

May 10, 2021

SELL
$207.02 - $241.31 $10.8 Million - $12.6 Million
-52,409 Reduced 76.18%
16,391 $3.52 Million
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $3.86 Million - $5.15 Million
18,641 Added 37.16%
68,800 $16.3 Million
Q3 2020

Nov 10, 2020

BUY
$255.65 - $303.1 $12.8 Million - $15.2 Million
50,159 New
50,159 $13.6 Million
Q1 2019

May 01, 2019

SELL
$163.73 - $194.7 $687,666 - $817,740
-4,200 Closed
0 $0
Q4 2018

Jan 31, 2019

BUY
$151.91 - $192.21 $638,022 - $807,282
4,200 New
4,200 $696,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Pictet & Cie (Europe) Sa Portfolio

Follow Pictet & Cie (Europe) Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.